Shilpa Medicare’s arm files first drug master file of Recombinant Human Albumin 20%

04 Jun 2024 Evaluate

Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals has filed its first Drug Master File of Recombinant Human Albumin 20% with United States Food and Drug Administration (USFDA). This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive. Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

935.80 55.90 (6.35%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.